Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticlePERSPECTIVES IN PHARMACOLOGY

Pharmacogenetic Considerations in Diseases of Cardiac Ion Channels

Arun Anantharam, Steven M. Markowitz and Geoffrey W. Abbott
Journal of Pharmacology and Experimental Therapeutics December 2003, 307 (3) 831-838; DOI: https://doi.org/10.1124/jpet.103.054569
Arun Anantharam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven M. Markowitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey W. Abbott
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Phenotypic variation within a species arises from differences in genetic makeup between individuals. This inherent diversity empowers the species as a whole to explore and expand into new environmental niches and also to survive new stressors within an ever-changing environment. Paradoxically, one class of stressors currently challenging the human population is therapeutic drugs: medications designed to combat disease are often associated with a host of nonspecific side effects. Following earlier studies of the involvement of some cardiac ion currents in unwanted drug interactions, recent reports have identified not only the ion channel subunits involved but also a range of mutations and single nucleotide polymorphisms in ion channel genes that predispose to both drug-induced and familial cardiac arrhythmia. The tendency for individuals harboring specific, often common, gene variants to succumb to life-threatening cardiac arrhythmia, and the contribution of other factors such as drug interaction to disease etiology in these cases, are discussed here together with potential pharmacogenetic strategies for arrhythmia circumvention and therapy.

Footnotes

  • ↵1 Most inwardly rectifying K+ channels are formed by coassembly of four principal subunits each with only two transmembrane domains and a membrane-embedded pore region; they possess no intrinsic voltage sensor and are inwardly rectifying because of blockade at depolarized voltages by intracellular moieties such as Mg2+ ions or polyamines.

  • G.W.A. is supported financially by an American Heart Association National Scientist Development Grant and a Greenberg Atrial Fibrillation Grant.

  • DOI: 10.1124/jpet.103.054569.

  • ABBREVIATIONS: ECG, electrocardiogram; MiRP, MinK-related peptide; JLNS, Jervell and Lange-Nielsen syndrome; AF, atrial fibrillation; Kv channel, voltage-gated potassium channel; Nav channel, voltage-gated sodium channel; SNP, single nucleotide polymorphism.

    • Received August 5, 2003.
    • Accepted September 2, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 307 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 307, Issue 3
1 Dec 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacogenetic Considerations in Diseases of Cardiac Ion Channels
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticlePERSPECTIVES IN PHARMACOLOGY

Pharmacogenetic Considerations in Diseases of Cardiac Ion Channels

Arun Anantharam, Steven M. Markowitz and Geoffrey W. Abbott
Journal of Pharmacology and Experimental Therapeutics December 1, 2003, 307 (3) 831-838; DOI: https://doi.org/10.1124/jpet.103.054569

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticlePERSPECTIVES IN PHARMACOLOGY

Pharmacogenetic Considerations in Diseases of Cardiac Ion Channels

Arun Anantharam, Steven M. Markowitz and Geoffrey W. Abbott
Journal of Pharmacology and Experimental Therapeutics December 1, 2003, 307 (3) 831-838; DOI: https://doi.org/10.1124/jpet.103.054569
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Cardiac Ion Currents and Arrhythmia
    • KCNQ1 and MinK Mutations Cause Inherited Long QT Syndrome and Deafness
    • HERG and MiRP1 Mutations Associate with Inherited Long QT Syndrome
    • HERG and MiRP1 Are Key Molecular Determinants in Acquired Long QT Syndrome
    • Lethal Mutations and Subtle SNPs in the SCN5A Gene
    • Gene-Guided Therapies
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Acute and Delayed Clinical Manifestations of OP Toxicity
  • Miltefosine as Mediator of the Immune Response
  • Histamine Receptor Knockout Mice
Show more Perspectives in Pharmacology

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics